2411871-58-2
2411871-58-2
Chemical Structure
Voxalatamab
Synonym(s): JNJ-63898081; JNJ-081
- CAS No.: 2411871-58-2
- Formula:N/A
- Molecular Weight:(144.68 kDa)
IUPAC Name: 6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)-N-(4-phenoxyphenyl)quinazolin-4-amine
SMILES: [Voxalatamab]
Biological Activity: Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and CD3. Voxalatamab attacks PSMA-expressing tumor cells by activating T cells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Voxalatamab | 99.90% | Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and CD3. Voxalatamab attacks PSMA-expressing tumor cells by activating T cells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lim EA, et al. Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2023 Jun;21(3):366-375. [Content Brief]
- [2]. Jonas S Heitmann, et al. Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives. Cancers (Basel). 2021 Feb 1;13(3):549. [Content Brief]
